FDA Grants De Novo Classification to Neuropacs™, a First-in-Class AI-Based MRI Diagnostic Aid for Parkinsonian Syndromes (Business Wire)
UF startup neuropacs™ Corp. received FDA De Novo classification for its diffusion MRI–based software designed to assist clinicians in evaluating Parkinsonian syndromes.
Neuropacs Closes Seed Round of Financing (Businesswire)
UF startup neuropacs™ Corp. announced the successful raise of over $1.0 million in early-stage capital.
JAMA Neurology Publishes Landmark Study Showing Neuropacs™ AI Technology Significantly Enhances the Diagnostic Accuracy of Parkinson’s Disease and Atypical Parkinsonism
UF startup neuropacs™ Corp., a leading innovator in AI-driven neurological diagnostics, announces the results of a prospective multicenter study that evaluated neuropacs™ AI technology for diagnosing Parkinson’s disease and atypical parkinsonism.